Jan 20, 2023
Companies have halted an advanced trial of an HIV vaccine because the shot was found to not prevent infection. Results from the stage 3 trial led to the determination that the vaccine "was not effective in preventing HIV infection compared to placebo among study participants," Johnson & Johnson and its partners said in a statement. The vaccine, dubbed Mosiaco, was developed by Janssen, a Johnson & Johnson subsidiary. The study's Data and Safety Monitoring Board, or a group of independent experts that was monitoring the research, made the determination. The study is being discontinued because of the determination, Johnson & Johnson said....